Device Trial Radar · NCT01823107
Feasibility Study of Meso BioMatrix Device for Breast Reconstruction
Last checked: Nov 20, 2026Latest source record: Sep 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Oct 2012
Primary completion
Jun 2017
Study completion Jun 29, 2017
Sponsor
- Lead sponsor
- Kensey Nash CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 4, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and feasibility of the use of Meso BioMatrix Acellular Peritoneum Matrix for the reinforcement of weakened soft tissue during 2-stage, tissue expander assisted breast reconstruction.
Conditions
- Breast Cancer
Interventions
Meso BioMatrix DeviceDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Breast Related Adverse EventsTime frame: 18 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Henry Ford Health System
Detroit, Michigan
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.